It has been about a month since the last earnings report for Reata Pharmaceuticals, Inc. (RETA). Shares have lost about 1.3% in that time frame, underperforming the S&P 500. Will the recent negative ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the ...

Biogen’s $7.3 billion buyout of Skyclarys-maker Reata Pharmaceuticals surprised some industry watchers last month. But it turns out Biogen wasn’t the only drugmaker jockeying for the Texas-based rare ...

Shares of Reata Pharmaceuticals (NASDAQ: RETA) got hammered in early trading Thursday, plunging as much as 43%. As of 11:18 a.m. ET, the stock was still down 42.7%. The catalyst that sent the clinical ...

Reata is paying AbbVie $330 million to reacquire the rights to bardoxolone methyl (bard), omav, and all next-generation Nrf2 activators. In 2010, Reata licensed to AbbVie the ex-U.S. rights for bard, ...

March 1 (Reuters) - Shares of Reata Pharmaceuticals Inc RETA.O soared 175% to hit a one-year high in early trading on Wednesday, after the U.S. Food and Drug Administration (FDA) approved its rare ...

(Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the ...

Drug developer Reata Pharmaceuticals Inc. plans to move into a new headquarters in Plano to keep up with its growth. Reata is transitioning from a clinical stage company to one that will soon market ...

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage ...

Along with its Q3 results, Reata provided an update on its recent discussions with the Food and Drug Administration. The FDA's review process for omaveloxolone as a treatment for Friedreich’s ataxia ...